Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular imaging of the human brain. Over the past years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided evidence for the key role of serotonergic pathology in patients with Parkinson's disease (PD). Here, we review the role of SERT in the development of motor and nonmotor complications in patients with PD, and we performed a meta-analysis to identify the patterns of SERT pathology and the relevance to symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus, and hypothalamus and associations with aging, PD progression, development of dyskinesias, and cognitive decline were observed. ANN NEUROL 2017;81:171-180 S erotonergic dysfunction occurs early in the course of Parkinson's disease (PD) 1 and is characterized by the presence of Lewy bodies in raphe nuclei 2 and by loss of terminals in serotonin-containing neurons. 3 According to Braak's staging of PD, the pathological processes in serotonergic median raphe nuclei occur in stage 2, which is a presymptomatic stage preceding the lesions of dopaminergic midbrain neurons. 2 Biochemical and postmortem studies have also confirmed that the serotonergic system is affected in PD.
staging of PD, the pathological processes in serotonergic median raphe nuclei occur in stage 2, which is a presymptomatic stage preceding the lesions of dopaminergic midbrain neurons. 2 Biochemical and postmortem studies have also confirmed that the serotonergic system is affected in PD. [4] [5] [6] Positron emission tomography (PET) is a powerful technique that has been used for the quantification of serotonin pathology in vivo in patients with PD. 7, 8 This molecular imaging technique allows to measure in vivo metabolic processes and aid in the understanding of etiology and pathophysiology of diseases and in the identification of novel pharmacological targets. Several PET ligands have been developed for the evaluation of serotonergic receptors and serotonin transporter (SERT). 9 [ 11 C]-3-amino-4-(2-dimethylaminomethylphenylsulfaryl)-benzonitrile ([ 11 C]DASB) is a second-generation PET ligand with high selectivity for the SERT, 9 which is superior compared to first-generation ligands. 10 Over the past years, a number of PET studies imaging the SERT have been used and provided evidence for the key role of serotonergic pathology in patients with PD. 3, 4 The aims of this study are to systematically review the role of SERT in the development of motor and nonmotor symptoms in PD and to examine in vivo SERT changes in PD patients compared to healthy controls (HCs), as measured by [ published before October 1, 2016 . Studies were identified, combining the following major medical subject headings: "Parkinson's disease" and "PET" combined with text and key words. Additional eligible studies were identified screening the reference lists of studies included in our analysis.
Specific Aims for Meta-Analyses
The current study aims to systematically examine the consistency of in vivo SERT changes in PD versus HCs as measured by 
Selection Criteria
All selected titles and abstracts were independently reviewed by two investigators (G.P., F.N.). Studies were excluded if the title and/or abstract were not appropriate for the aim of the review. Full texts were subsequently obtained for eligible studies or when the relevance of an article could not be certainty excluded. Selected studies were eligible if they met the following criteria: (1) cross-sectional, case control, or longitudinal [ 11 C]DASB PET studies including PD patients with confirmed diagnosis based on the UK Brain Bank criteria; (2) studies published in peer-reviewed journals; (3) [ 11 C]DASB PET measures reported as mean 6 standard deviation; and (4) studies not including HCs were included in the meta-analysis only for secondary analyses within PD subgroups. In cases of two or more studies from the same center, we have carefully checked for overlapping samples by contacting the corresponding authors to verify that there was not a significant overlap in the samples. For studies including overlapping PD samples, we have included only the study with the largest sample in the meta-analysis.
Risk of Bias in Included Studies
The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) 14 that includes selection, comparability, and exposure (case-control studies) or outcome (cohort studies). The scale ranged from zero to six stars, with the highest degree representing the greatest methodological quality. Disagreement was resolved by consensus and by opinion of a third reviewer (M.P.). The presence of publication bias was explored by performing the test for asymmetry of the funnel plot by Egger.
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Data Extraction
Two reviewers (G.P., F.N.) independently completed the data extraction and variables extracted were study year, author first name, sex, mean age of participants, number of participants, disease duration (years), Hoehn C]DASB binding in PD patients compared to HCs. The results were pooled using the inverse variance method. Heterogeneity was assessed using the I 2 index statistic, which accounts for between-study (or interstudy) variability as opposed to within-study (or intrastudy) variability. Heterogeneity was considered substantial if the I 2 value was greater than 40%. 16 Because of the heterogeneity of samples, a random-effect model was used to summarize data instead of a fixed-effect model, independently of statistical evidence for heterogeneity. 17 To investigate the impact of individual studies on the results, we undertook one study-removed analysis by omitting one study in each turn and recalculating the pooled estimates on remaining studies. 18 To explore the influence of potential effect modifiers on [ 11 C]DASB binding, metaregression analyses were performed to test age, sex (male %), disease duration, H&Y scale, UPDRS total score and UPDRS Part-III motor score, MMSE, and quality of the study (NOS), when at least 10 studies were available for each modifier. For all metaregression analyses, a random-effect model was used to take into account the mean of a distribution of effects across studies. To estimate the additive (between-study) component of variance s
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, the restricted maximum likelihood method was used to take into account the occurrence of residual heterogeneity, not explained by the potential effect modifiers. 19 All reported test results were two-tailed and statistical significance was set at a p < 0.05. The role of serotonergic mechanisms in the development of levodopa-induced dyskinesias (LIDs) in PD patients have been evaluated in four PET studies. [25] [26] [27] [28] First, by using [ 27 which demonstrated that SERT to DAT ratio increases as PD progresses in patients who experience LIDs. Overall, these findings suggest that when the dopaminergic innervation in the striatum is critically low, the serotonergic system plays an important role in development of LIDs. Smith et al 28 used [ 11 C]DASB PET and found relative preservation of SERT binding in the globus pallidus in PD patients with LIDs that was associated with a significant rise in pallidal synaptic dopamine levels, detected by [ 11 C]raclopride PET, and suggesting that pallidal serotonergic terminals are also important in the development of LIDs in PD.
Systematic Review
Serotonergic mechanisms, such as excessive serotonergic striatal innervation and high serotonin to dopamine striatal terminal ratio, have been also associated with the development of graft-induced dyskinesias in PD patients who underwent striatal transplantation with fetal ventral mesencephalic (FVM) tissue. 29, 30 Nonmotor Symptoms The pathophysiology of non-motor symptoms in PD remains unclear, and serotonergic pathology has been hypothesized as one of the main mechanisms underlying depression, 22, [34] [35] [36] fatigue, 37 apathy, 38, 39 weight changes, 40 sleep problems, 41, 42 olfactory dysfunction, 43 and visual hallucinations in PD. 44 An [
11 C]DASB PET study in transplanted PD patients with dopamine-rich FVM tissue and successful dopaminergic reinnervation has shown widespread progressive decline of SERT binding up to three decades following diagnosis that could be associated with the development of non-motor symptoms in PD. 45 We have found three studies investigating SERT levels in PD depression. 22, 34, 35 In two of them, 34, 35 an increase of SERT binding in limbic structures 34 and in raphe nuclei 35 was found in depressed compared with nondepressed PD patients. Higher SERT levels were correlated with worse depressive symptoms as assessed by Hamilton Depression Rating Scale 34, 35 or Beck Depression Inventory-II. 35 A third study 22 found no correlation between depression and SERT levels in PD. However, this study was not conducted on PD patients with a clinical diagnosis of depression. The prevalence of depression in PD is higher than the general population. This might be attributed to the combination of SERT upregulation, which is typical of depression, and loss of serotonergic terminals, which is typical of PD. We found only one study investigating the relationship between SERT and fatigue. 37 Compared to PD patients without fatigue, PD patients with fatigue showed around 75% [ 11 C]DASB binding reduction in putamen, caudate, ventral striatum, thalamus, cingulate, and amygdala. SERT dysfunction has also been associated with apathy in one recent study. 38 showed that visual hallucinations were associated with increased 5-HT2A binding in ventral visual pathway, dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. 44 These findings suggested that abnormalities in serotonin neurotransmission could be involved in the neural mechanisms underlying the development of visual hallucinations that are associated with PD and support the use of selective 5-HT2A receptor antagonists for their treatment. 44 
Results of Meta-Analysis
Of 6,380 articles identified by the initial search, 49 were retrieved for more detailed evaluation. We then excluded 29 PET and single-positron emission computed tomography studies, which used ligands with no specific SERT binding. Finally, 20 [ 11 C]DASB PET studies were included in the meta-analysis. 1, [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] 34, 35, 37, [40] [41] [42] 45, 47, 48 The study cohorts in this meta-analysis included 234 PD patients and 225 HCs ( Table 1 ). The quality of included studies was moderate or good, varying from four to six NOS stars (Table 2) . (Fig 1) .
In presence of relevant heterogeneity (I 2 > 40%)
and where more than 10 [ 11 C]DASB studies were included in the analysis, a metaregression was carried out for the primary outcome of [ 11 C]DASB binding in putamen, caudate, ventral striatum, thalamus, and hypothalamus (Fig 2) . Longer disease duration was correlated with decreased [ 11 C]DASB binding within putamen (Fig 2A;  n 37 one in PD patients with RBD, 41 and one with sleep-disordered breathing 42 ; thus, no meta-analyses have been performed for these outcomes.
PUBLICATION BIAS AND SENSITIVITY ANALYSIS.
For the primary outcome, the Egger test was not significant in any of the brain areas, with the exception of ventral striatum (p 5 0.011), indicating a risk of publication bias only for this area. Robustness of meta-analytic findings was confirmed by sequentially removing each study and reanalyzing the remaining data set (producing a new analysis for each study removed). The results remained unchanged regarding direction and magnitude (data not shown). Metaregression revealed no significant effect of the quality of the studies (NOS scores) on [ 
Discussion
To the best of our knowledge, this is the first comprehensive systematic review and meta-analysis investigating SERT changes in PD. With regard to motor symptoms, we found, in our systematic review, that SERT dysfunction is associated with the development of tremor and dyskinesias in PD. With regard to nonmotor symptoms, we found, in our systematic review, that SERT dysfunction is associated with depression, fatigue, apathy, and weight changes. Associations with sleep problems and olfactory dysfunction need further investigations whereas visual hallucinations seems to be related with impairment of serotonergic receptors more than SERT levels. However, because of the small number of studies and relatively small sample sizes, the conclusions regarding the relationship between serotonergic dysfunction and clinical features of PD need further evaluations.
Our meta-analysis demonstrates that SERT binding is reduced in patients with PD in rostral and caudal raphe, putamen, caudate, ventral striatum, thalamus, and hypothalamus. Reduced SERT binding in putamen is associated with longer duration of the disease. PD patients with dyskinesias showed preserved SERT binding in putamen compared to nondyskinetic PD patients. Lower [
11 C]DASB binding in caudate is associated with worse cognitive function and older age. The widespread decrease of SERT binding in patients with PD confirms the important role of serotonergic system dysfunction in the pathophysiology of PD. The highest decreases in SERT binding were observed in the rostral raphe and caudate followed by putamen, thalamus, ventral striatum, caudal raphe, and hypothalamus. According to Braak's staging, raphe nuclei are one of the first brain regions affected by Lewy body and neurite deposition and could be preceding dopaminergic pathology and the development of motor symptoms. 2 Later stages involve pathology in the hypothalamus, striatum, and thalamus. Also, previous molecular imaging and postmortem studies have reported a preferential loss of SERT binding in the caudate compared to the putamen. 1, 4, 6 Our meta-analytical findings are in line with these observations. Our findings demonstrate that loss of SERT binding in caudate and putamen have important clinical relevance. The risk of cognitive impairment increases with age, and our findings show that SERT binding in caudate is reduced with advanced age and is associated with worse cognitive scores. Several pathological processes have been implicated in the development of cognitive impairment in PD, and these include degeneration of subcortical cholinergic and dopaminergic projections, microglial activation, and neocortical pathology associated with misfolded protein depositions or vascular pathology. 49 A recent study has demonstrated that the combined presence of striatal and cortical bamyloidopathy is associated with greater cognitive impairment than cortical b-amyloidopathy alone in PD, 50 indicating an important role of striatal b-amyloid pathology in the development of cognitive impairment in PD. Additional studies have shown that b-amyloid levels could affect serotonin signaling, 51, 52 and that striatal serotoninergic degeneration may promote the development of cerebral amyloidopathy in patients with PD. 48 Our findings confirm that SERT binding in putamen plays a crucial role in the pathophysiology of dyskinesias in patients with PD. Our data show relative preservation of SERT binding within putamen in dyskinetic PD compared to nondyskinetic PD patients. Previous experimental studies have demonstrated that abnormal involuntary movements in rats are critically dependent on the integrity of serotonergic projections, and that removal of striatal serotonergic afferents or the dampening serotonergic activity with serotonin receptor agonists attenuated abnormal involuntary movements. [53] [54] [55] Clinical and molecular imaging studies in humans have shown that striatal serotonergic terminals contribute to the abnormal levodopa-or graftinduced increases in synaptic dopamine levels in PD patients and in the development of dyskinesias. [25] [26] [27] [28] [29] [30] 56 Although SERT binding in putamen decreases with the progression of the disease it remains unclear why PD patients with dyskinesias have relatively preserved putaminal serotonergic function. It is possible that SERT upregulation or interactions with other systems may play a role. Future studies will be needed to elucidate this mechanism.
In this meta-analysis, data showed that reduced SERT binding in the hypothalamus was associated with male sex. Previous studies on sex differences in PD have shown a more benign phenotype in women with PD, which could be the result of higher physiological striatal dopamine levels, possibly attributed to the activity of estrogens. 57 Estrogens also regulate gene expression of serotonin in midbrain and hypothalamus and their effect in SERT binding cannot be excluded. 58 The main strength of our meta-analysis was the systematic strategy and the inclusion of PET studies with high selectivity for SERT. The main limitations are that the meta-analysis was not carried out on individual patient data stratified for different PD symptoms and was limited to non-cortical regions. We have decided to exclude cortical areas attributed to the lack of data and the heterogeneity of reporting results among the studies. Additional limitations included the small sample sizes and low quality of some studies that represent a potential risk of bias (eg, for the hypothalamus). Another possible limitation is the presence of publication bias for ventral striatum. The risk of bias evidenced by the funnel plot asymmetry needs to be interpreted considering the small number of studies included.
Future Directions
Serotonergic pathology plays a key role in the progressive neurodegenerative process in the course of PD, and PET imaging such as [ 11 C]DASB PET provides the means for direct visualization and quantification in vivo in patients with PD. Although several studies have been performed using serotonergic PET ligands, the vast majority of associations between serotonergic pathology and PD symptoms requires further validation. Future [ 11 C]DASB PET studies in subjects at higher risk for developing PD and in familial forms of PD may shed light for the premanifest stages and pathology. Currently, all studies have been cross-sectional, and further studies with longitudinal designs, perhaps using various PET ligands for the quantification of serotonergic markers, are needed to better understand the progression of serotonergic pathology and the relation to symptoms and complications in patients with PD.
